Financial Ratios Spire Healthcare Group plc
Stocks
SPI
GB00BNLPYF73
Healthcare Facilities & Services
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 218.00 GBX | -0.46% |
|
+1.16% | +30.54% |
| 07-15 | Spire Healthcare Announces as Exclusive Team GB Official Healthcare Services Partner | CI |
| 07-14 | CPI Brings Relief, but Oil Is Back in Charge |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 2.36 | 3 | 3.56 | 3.81 | 3.86 | |||||
Return on Total Capital | 2.66 | 3.39 | 4.05 | 4.39 | 4.45 | |||||
Return On Equity % | -1.26 | 1.15 | 3.81 | 3.5 | 2.31 | |||||
Return on Common Equity | -1.37 | 1.19 | 3.71 | 3.41 | 2.2 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 44.4 | 44.92 | 45.93 | 45.24 | 45.33 | |||||
SG&A Margin | 1.11 | 1.13 | 1.37 | 38.9 | 38.6 | |||||
EBITDA Margin % | 13.5 | 14.15 | 14.19 | 13.91 | 13.63 | |||||
EBITA Margin % | 7.4 | 8.79 | 9.37 | 9.48 | 9.31 | |||||
EBIT Margin % | 7.4 | 8.79 | 9.33 | 9.35 | 9.22 | |||||
Income From Continuing Operations Margin % | -0.8 | 0.68 | 2.05 | 1.72 | 1.09 | |||||
Net Income Margin % | -0.88 | 0.72 | 2.01 | 1.68 | 1.04 | |||||
Net Avail. For Common Margin % | -0.88 | 0.72 | 2.01 | 1.68 | 1.04 | |||||
Normalized Net Income Margin | -0.36 | 1.05 | 1.64 | 1.76 | 1.67 | |||||
Levered Free Cash Flow Margin | 5.99 | 0.48 | 3.69 | 2.58 | 4.2 | |||||
Unlevered Free Cash Flow Margin | 10.91 | 4.96 | 7.79 | 6.55 | 8.2 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.51 | 0.55 | 0.61 | 0.65 | 0.67 | |||||
Fixed Assets Turnover | 0.72 | 0.76 | 0.85 | 0.92 | 0.94 | |||||
Receivables Turnover (Average Receivables) | 17.28 | 17.64 | 16.73 | 16.03 | 15.95 | |||||
Inventory Turnover (Average Inventory) | 15.81 | 16.34 | 17.31 | 18.21 | 18.61 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.15 | 0.78 | 0.69 | 0.66 | 0.64 | |||||
Quick Ratio | 0.94 | 0.57 | 0.48 | 0.42 | 0.39 | |||||
Operating Cash Flow to Current Liabilities | 0.61 | 0.64 | 0.68 | 0.69 | 0.7 | |||||
Days Sales Outstanding (Average Receivables) | 21.12 | 20.69 | 21.82 | 22.84 | 22.88 | |||||
Days Outstanding Inventory (Average Inventory) | 23.09 | 22.34 | 21.09 | 20.1 | 19.61 | |||||
Average Days Payable Outstanding | 32.42 | 32.85 | 32.4 | 32.81 | 36.15 | |||||
Cash Conversion Cycle (Average Days) | 11.79 | 10.18 | 10.51 | 10.13 | 6.34 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 179.63 | 164.23 | 170.37 | 171.52 | 176.95 | |||||
Total Debt / Total Capital | 64.24 | 62.15 | 63.01 | 63.17 | 63.89 | |||||
LT Debt/Equity | 166.4 | 151.03 | 156.57 | 157.4 | 162.07 | |||||
Long-Term Debt / Total Capital | 59.51 | 57.16 | 57.91 | 57.97 | 58.52 | |||||
Total Liabilities / Total Assets | 68.5 | 66.43 | 67.75 | 68.15 | 68.71 | |||||
EBIT / Interest Expense | 0.94 | 1.23 | 1.39 | 1.44 | 1.41 | |||||
EBITDA / Interest Expense | 2.06 | 2.37 | 2.52 | 2.55 | 2.54 | |||||
(EBITDA - Capex) / Interest Expense | 1.26 | 1.35 | 1.6 | 1.44 | 1.8 | |||||
Total Debt / EBITDA | 7.07 | 5.86 | 5.46 | 5.1 | 5.01 | |||||
Net Debt / EBITDA | 5.94 | 5.47 | 5.22 | 4.92 | 4.88 | |||||
Total Debt / (EBITDA - Capex) | 11.54 | 10.3 | 8.61 | 9.02 | 7.06 | |||||
Net Debt / (EBITDA - Capex) | 9.69 | 9.63 | 8.24 | 8.71 | 6.88 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 20.25 | 8.34 | 13.39 | 11.2 | 4.54 | |||||
Gross Profit, 1 Yr. Growth % | 7.77 | 9.61 | 15.94 | 9.52 | 4.75 | |||||
EBITDA, 1 Yr. Growth % | 12.17 | 15.06 | 15.65 | 9.19 | 2.43 | |||||
EBITA, 1 Yr. Growth % | 22.06 | 31.75 | 24.17 | 12.76 | 2.72 | |||||
EBIT, 1 Yr. Growth % | 22.06 | 31.75 | 23.59 | 11.44 | 3.04 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -96.2 | -192.13 | 240.24 | -6.81 | -33.85 | |||||
Net Income, 1 Yr. Growth % | -95.85 | -188.66 | 217.44 | -6.96 | -35.43 | |||||
Normalized Net Income, 1 Yr. Growth % | -64.36 | -343.24 | 106.11 | 19.31 | -1.22 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -95.86 | -186.78 | 214.3 | -6.06 | -35.48 | |||||
Accounts Receivable, 1 Yr. Growth % | -3.38 | 16.06 | 22.6 | 10.73 | -0.1 | |||||
Inventory, 1 Yr. Growth % | 6.91 | 1 | 9.11 | 5.19 | -0.86 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 1.19 | 1.99 | 2.17 | 2.76 | 1.73 | |||||
Total Assets, 1 Yr. Growth % | 6.3 | -3.47 | 5.94 | 2.41 | 1.45 | |||||
Tangible Book Value, 1 Yr. Growth % | -3.6 | 2.77 | -21.05 | 3.09 | -4.15 | |||||
Common Equity, 1 Yr. Growth % | 0.42 | 3.02 | 1.22 | 1.15 | -0.75 | |||||
Cash From Operations, 1 Yr. Growth % | 15.09 | -1.2 | 18.67 | 9.37 | 2.76 | |||||
Capital Expenditures, 1 Yr. Growth % | 48.71 | 26.55 | -3.76 | 30.27 | -30.19 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 30.66 | -91.11 | 480.75 | -22.23 | 70.23 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 16.12 | -50.23 | 83.37 | -6.46 | 30.89 | |||||
Dividend Per Share, 1 Yr. Growth % | - | - | 320 | 9.52 | -34.78 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 6.2 | 14.14 | 10.84 | 12.29 | 7.82 | |||||
Gross Profit, 2 Yr. CAGR % | 4.32 | 8.68 | 12.73 | 12.68 | 7.11 | |||||
EBITDA, 2 Yr. CAGR % | -4.21 | 12.88 | 14.4 | 12.26 | 5.76 | |||||
EBITA, 2 Yr. CAGR % | -8.4 | 25.33 | 26.19 | 18.14 | 7.62 | |||||
EBIT, 2 Yr. CAGR % | -8.4 | 25.33 | 25.9 | 17.35 | 7.16 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 11.18 | -81.28 | 77.05 | 78.07 | -21.48 | |||||
Net Income, 2 Yr. CAGR % | 16.07 | -80.83 | 67.76 | 71.86 | -22.49 | |||||
Normalized Net Income, 2 Yr. CAGR % | -31.76 | 6.07 | 107.76 | 56.81 | 8.56 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 16.07 | -81.04 | 65.15 | 71.83 | -22.15 | |||||
Accounts Receivable, 2 Yr. CAGR % | 9.98 | 5.89 | 19.29 | 16.51 | 5.17 | |||||
Inventory, 2 Yr. CAGR % | 12.08 | 3.91 | 4.98 | 7.13 | 2.12 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | -0.32 | 1.59 | 2.08 | 2.46 | 2.24 | |||||
Total Assets, 2 Yr. CAGR % | -1.09 | 1.3 | 1.13 | 4.16 | 1.93 | |||||
Tangible Book Value, 2 Yr. CAGR % | -5.77 | -0.46 | -9.92 | -9.79 | -0.59 | |||||
Common Equity, 2 Yr. CAGR % | -13.11 | 1.71 | 2.11 | 1.18 | 0.2 | |||||
Cash From Operations, 2 Yr. CAGR % | -4.54 | 6.64 | 8.28 | 13.93 | 6.01 | |||||
Capital Expenditures, 2 Yr. CAGR % | 6.94 | 37.19 | 10.36 | 11.64 | -4.64 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 7.73 | -66.23 | -12.24 | 112.52 | 15.06 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 4.89 | -24.35 | -5.88 | 30.97 | 10.65 | |||||
Dividend Per Share, 2 Yr. CAGR % | - | - | - | 114.48 | -15.48 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 5.91 | 6.91 | 13.89 | 10.96 | 9.64 | |||||
Gross Profit, 3 Yr. CAGR % | 4.25 | 6.05 | 11.05 | 11.65 | 9.97 | |||||
EBITDA, 3 Yr. CAGR % | -2.2 | 1.39 | 13.17 | 12.56 | 8.88 | |||||
EBITA, 3 Yr. CAGR % | -4.96 | 2.6 | 23.83 | 21.42 | 12.76 | |||||
EBIT, 3 Yr. CAGR % | -4.96 | 2.6 | 23.63 | 20.88 | 12.38 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 346.47 | 4.43 | -50.77 | 42.95 | 28.01 | |||||
Net Income, 3 Yr. CAGR % | 359.47 | 6.1 | -51.13 | 37.83 | 24.01 | |||||
Normalized Net Income, 3 Yr. CAGR % | -25.45 | 13.7 | 25.92 | 72.69 | 34.42 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 360.37 | 5.35 | -51.65 | 36.84 | 23.96 | |||||
Accounts Receivable, 3 Yr. CAGR % | 4.64 | 11.97 | 11.19 | 16.36 | 10.69 | |||||
Inventory, 3 Yr. CAGR % | 10.99 | 8.26 | 5.62 | 5.05 | 4.4 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | -0.48 | 0.45 | 1.78 | 2.3 | 2.22 | |||||
Total Assets, 3 Yr. CAGR % | -0.28 | -1.89 | 2.82 | 1.55 | 3.25 | |||||
Tangible Book Value, 3 Yr. CAGR % | -4.53 | -3 | -7.86 | -5.78 | -7.94 | |||||
Common Equity, 3 Yr. CAGR % | -9.22 | -8.04 | 1.55 | 1.79 | 0.54 | |||||
Cash From Operations, 3 Yr. CAGR % | 0.22 | -3.44 | 10.5 | 8.64 | 10.07 | |||||
Capital Expenditures, 3 Yr. CAGR % | -2.03 | 13.11 | 21.89 | 16.4 | -4.54 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 17.38 | -53.39 | -0.39 | -15.7 | 97.37 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 9.82 | -18.46 | 0.61 | -6.08 | 30.94 | |||||
Dividend Per Share, 3 Yr. CAGR % | - | -27.28 | - | - | 44.22 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 3.61 | 5.17 | 7.86 | 9.03 | 11.42 | |||||
Gross Profit, 5 Yr. CAGR % | 2.2 | 4.14 | 7.56 | 8.65 | 9.46 | |||||
EBITDA, 5 Yr. CAGR % | -1.45 | 2.57 | 3.86 | 5.26 | 10.1 | |||||
EBITA, 5 Yr. CAGR % | -5.5 | 2.76 | 5.96 | 7.97 | 17 | |||||
EBIT, 5 Yr. CAGR % | -5.5 | 2.76 | 5.86 | 7.68 | 16.76 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | -30.17 | -13.36 | 208.4 | 29.28 | -40.67 | |||||
Net Income, 5 Yr. CAGR % | -28.96 | -12.53 | 207.07 | 28.68 | -41.23 | |||||
Normalized Net Income, 5 Yr. CAGR % | -40.95 | -22.45 | 18.34 | 25.49 | 18.67 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -28.88 | -12.92 | 205.5 | 28.12 | -41.5 | |||||
Accounts Receivable, 5 Yr. CAGR % | 1.64 | 2.44 | 10.27 | 13.77 | 8.75 | |||||
Inventory, 5 Yr. CAGR % | 7.42 | 6.17 | 8.55 | 7.81 | 4.21 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 9.4 | 8.85 | 0.54 | 1.25 | 1.96 | |||||
Total Assets, 5 Yr. CAGR % | 5.35 | 4.49 | 0.28 | 0.48 | 2.46 | |||||
Tangible Book Value, 5 Yr. CAGR % | -6.25 | -5.83 | -6.72 | -5.78 | -5.02 | |||||
Common Equity, 5 Yr. CAGR % | -7.28 | -6.77 | -4.85 | -4.45 | 1 | |||||
Cash From Operations, 5 Yr. CAGR % | 0.71 | 7.93 | 3.37 | 3.16 | 8.69 | |||||
Capital Expenditures, 5 Yr. CAGR % | -14.25 | -5.95 | 2.75 | 12.52 | 10.36 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 34.68 | 3.02 | 4.12 | -7.35 | 5.53 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 117.8 | 50.51 | 3.04 | -2.03 | 4.51 | |||||
Dividend Per Share, 5 Yr. CAGR % | - | -33.34 | -11.18 | 12.09 | - |
- Stock Market
- Stocks
- SPI Stock
- Financials Spire Healthcare Group plc
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















